Brandon Lee, MD
Ophthalmology · Honolulu, HINPI 1801042007
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 374 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by Alcon at 25.5% of the total.
Across 374 payments — averaging $35.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- AbbVie$1K
- Amgen$1K
- Glaukos Corporation$862
- Sight Sciences, Inc.$860
- Aerie Pharmaceuticals, Inc.$823
- plus $5K from 25 others
What the payments were for
- Food & beverage$13,051100%
- Education$170%
- Entertainment$380%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 98 | $3,344 |
| AbbVie(2 entities) | 61 | $1,083 |
| Amgen(2 entities) | 14 | $1,043 |
| Glaukos Corporation | 19 | $862 |
| Sight Sciences, Inc. | 17 | $860 |
| Aerie Pharmaceuticals, Inc. | 18 | $823 |
| Johnson & Johnson Surgical Vision, Inc. | 16 | $744 |
| Genentech USA, Inc. | 16 | $617 |
| Bausch & Lomb Americas Inc. | 15 | $449 |
| Novartis | 18 | $428 |
| Sun Pharmaceutical Industries Inc. | 13 | $410 |
| Regeneron Healthcare Solutions, Inc. | 5 | $400 |
| Dompe US, Inc. | 13 | $362 |
| Tarsus Pharmaceuticals, Inc. | 13 | $324 |
| Ivantis, Inc | 2 | $229 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $212 |
| Shire North American Group Inc | 5 | $169 |
| Oyster Point Pharma, Inc. | 7 | $167 |
| NEW World Medical,inc. | 2 | $145 |
| Hoffmann-la Roche Limited | 1 | $81 |
| Eyevance Pharmaceuticals LLC | 3 | $50 |
| Abbott | 2 | $48 |
| Harrow Eye, LLC | 1 | $44 |
| Optos, Inc. | 1 | $38 |
| Rxsight Inc | 2 | $36 |
| Galderma Laboratories, L.p. | 1 | $27 |
| Mallinckrodt Enterprises LLC | 1 | $26 |
| Kala Pharmaceuticals, Inc. | 1 | $25 |
| Beaver-visitec International, Inc. | 1 | $22 |
| Rayner Intraocular Lenses Limited | 1 | $22 |
| Coopervision Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rocklatan$845
- Rhopressa$738
- TEPEZZA$668
- OMNI(R) SURGICAL SYSTEM (US)$577
- Clareon$535
- VABYSMO$509
- DURYSTA$336
- iDoseTR$324
- VYZULTA$250
- Tecnis Multifocal Family of 1-piece IOLS$239
- EYLEA$230
- Hydrus Microstent$186
- iStent Infinite$164
- Photrexa Viscous and Photrexa$161
- XDEMVY$134
- EYLEA HD$132
- Tecnis IOL$132
- BEOVU$125
- enVista MX60 IOL$125
- Ahmed Glaucoma Valve$125
How this compares
$13,106 in reported general payments places this provider in the 80th percentile of 120 ophthalmology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 125 | $134,591 |
| RocklatanNetarsudil Mesylat/Latanoprost | 71 | $75,068 |
| LumiganBimatoprost | 71 | $48,510 |
| VyzultaLatanoprostene Bunod | 42 | $40,358 |
| XiidraLifitegrast | 24 | $37,810 |
| Latanoprost | 1,045 | $29,620 |
| RhopressaNetarsudil Mesylate | 41 | $24,267 |
| CequaCyclosporine | 22 | $18,379 |
| CombiganBrimonidine Tartrate/Timolol | 34 | $15,540 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 212 | $13,347 |
| Alphagan PBrimonidine Tartrate | 25 | $11,664 |
| Travoprost | 13 | $7,805 |
| Restasis MultidoseCyclosporine | 11 | $7,546 |
| Brimonidine Tartrate | 142 | $5,986 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 324 | $5,909 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P, Restasis Multidose | $1,083 | $217,851266 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $823 | $99,335112 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $449 | $78,16866 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $410 | $18,37922 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $212 | $3,16921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 120 ophthalmology providers in Hawaii.
Other ophthalmology in Honolulu
- Neda NikpoorHonolulu$293K
- Carlton YuenHonolulu$175K
- Alan FaulknerHonolulu$135K
- Michael BennettHonolulu$108K
- Jeffrey PetersonHonolulu$77K
- Rupa WongHonolulu$72K
- Jon PortisHonolulu$20K
- Tyrie JenkinsHonolulu$19K
- John OlkowskiHonolulu$15K
- Claudia HootenHonolulu$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.